Han Yohan, Jones Timothy W, Dutta Saugata, Zhu Yin, Wang Xiaoyun, Narayanan S Priya, Fagan Susan C, Zhang Duo
Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia and Charlie Norwood VA Medical Center, Augusta, GA 30912, USA.
Center for Vaccines and Immunology, University of Georgia, Athens, GA 30602, USA.
Processes (Basel). 2021 Feb;9(2). doi: 10.3390/pr9020356. Epub 2021 Feb 15.
The enormous library of pharmaceutical compounds presents endless research avenues. However, several factors limit the therapeutic potential of these drugs, such as drug resistance, stability, off-target toxicity, and inadequate delivery to the site of action. Extracellular vesicles (EVs) are lipid bilayer-delimited particles and are naturally released from cells. Growing evidence shows that EVs have great potential to serve as effective drug carriers. Since EVs can not only transfer biological information, but also effectively deliver hydrophobic drugs into cells, the application of EVs as a novel drug delivery system has attracted considerable scientific interest. Recently, EVs loaded with siRNA, miRNA, mRNA, CRISPR/Cas9, proteins, or therapeutic drugs show improved delivery efficiency and drug effect. In this review, we summarize the methods used for the cargo loading into EVs, including siRNA, miRNA, mRNA, CRISPR/Cas9, proteins, and therapeutic drugs. Furthermore, we also include the recent advance in engineered EVs for drug delivery. Finally, both advantages and challenges of EVs as a new drug delivery system are discussed. Here, we encourage researchers to further develop convenient and reliable loading methods for the potential clinical applications of EVs as drug carriers in the future.
庞大的药物化合物库提供了无尽的研究途径。然而,一些因素限制了这些药物的治疗潜力,如耐药性、稳定性、脱靶毒性以及药物向作用部位的递送不足。细胞外囊泡(EVs)是由脂质双层界定的颗粒,由细胞自然释放。越来越多的证据表明,EVs作为有效的药物载体具有巨大潜力。由于EVs不仅可以传递生物信息,还能有效地将疏水性药物递送至细胞内,因此将EVs作为一种新型药物递送系统的应用已引起了相当大的科学关注。最近,装载有小干扰RNA(siRNA)、微小RNA(miRNA)、信使RNA(mRNA)、CRISPR/Cas9、蛋白质或治疗性药物的EVs显示出更高的递送效率和药物效果。在本综述中,我们总结了将货物装载到EVs中的方法,包括siRNA、miRNA、mRNA、CRISPR/Cas9、蛋白质和治疗性药物。此外,我们还介绍了用于药物递送的工程化EVs的最新进展。最后,讨论了EVs作为一种新型药物递送系统的优势和挑战。在此,我们鼓励研究人员进一步开发方便可靠的装载方法,以便未来将EVs作为药物载体进行潜在的临床应用。